MannKind Corp. of Valencia announced Tuesday that it reached a final resolution of the arbitration proceedings initiated by John Arditi, former senior director of good clinical practices and regulatory affairs for MannKind.
Arditi played a key role in preparing clinical sites for FDA inspection and was responsible for the company’s GCP compliance audit program, said a company spokesperson.
As a result of the resolution, MannKind announced that Arditi withdrew his claims against the firm for violation of the New Jersey Conscientious Employee Protection Act wrongful discharge, breach of contract, breach of the implied covenant of good faith and fair dealing, intentional infliction of emotional distress and defamation. MannKind also issued a statement by Arditi.
“I do not believe there was fraud or scientific misconduct on the part of investigators, nor do I believe there is any question regarding the reliability and integrity of the data collected in MannKind’s clinical trials while I was employed. I am proud that I was part of a team that achieved full GCP compliance with respect to the AFREZZA new drug application during my employment,” Arditi said.
